Annika Brinkmann
Overview
Explore the profile of Annika Brinkmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
622
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Otieno J, Ruis C, Onoja A, Kuppalli K, Hoxha A, Nitsche A, et al.
Nat Med
. 2024 Oct;
31(1):342-350.
PMID: 39442559
Monkeypox virus (MPXV) is endemic in western and Central Africa, and in May 2022, a clade IIb lineage (B.1) caused a global outbreak outside Africa, resulting in its detection in...
2.
Obermeier P, Plinke C, Brinkmann A, Lachmann R, Melchert J, Corman V, et al.
Emerg Infect Dis
. 2024 Jun;
30(7):1416-1419.
PMID: 38916584
In July 2023, clade IIb-associated mpox reemerged in Germany at low levels, mainly affecting men who have sex with men. We report a representative case and phylogeny of available genome...
3.
Diaz-Canova D, Moens U, Brinkmann A, Nitsche A, Okeke M
Front Immunol
. 2024 Apr;
15:1277447.
PMID: 38633245
Modified vaccinia virus Ankara (MVA) has been widely tested in clinical trials as recombinant vector vaccine against infectious diseases and cancers in humans and animals. However, one biosafety concern about...
4.
Brinkmann A, Pape K, Uddin S, Woelk N, Forster S, Jessen H, et al.
J Virol Methods
. 2024 Jan;
325:114888.
PMID: 38246565
We present an amplicon-based assay for MinION Nanopore sequencing of mpox virus (MPXV) genomes from clinical specimens, obtaining high-quality results with an average genome coverage of 99% for Ct values...
5.
Souza A, Brinkmann A, Esparza J, Nitsche A, Damaso C
mBio
. 2023 Sep;
14(5):e0188723.
PMID: 37729584
Modern smallpox vaccines, such as those used against mpox, are made from vaccinia viruses, but it is still unknown whether cowpox, horsepox, or vaccinia viruses were used in the early...
6.
Brinkmann A, Kohl C, Pape K, Bourquain D, Thurmer A, Michel J, et al.
Virus Genes
. 2023 May;
59(4):532-540.
PMID: 37256469
Poxviruses are known to evolve slower than RNA viruses with only 1-2 mutations/genome/year. Rather than single mutations, rearrangements such as gene gain and loss, which have been discussed as a...
7.
Nasri F, Kongkitimanon K, Wittig A, Cortes J, Brinkmann A, Nitsche A, et al.
Nucleic Acids Res
. 2023 May;
51(W1):W331-W337.
PMID: 37167010
The mpox virus (MPXV) is mutating at an exceptional rate for a DNA virus and its global spread is concerning, making genomic surveillance a necessity. With MpoxRadar, we provide an...
8.
Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Hellenbrand W, Perriat D, et al.
Infection
. 2023 Mar;
51(4):1093-1102.
PMID: 36913112
Purpose: COViK, a prospective hospital-based multicenter case-control study in Germany, aims to assess the effectiveness of COVID-19 vaccines against severe disease. Here, we report vaccine effectiveness (VE) against COVID-19-caused hospitalization...
9.
Stoliaroff-Pepin A, Peine C, Herath T, Lachmann J, Perriat D, Dorre A, et al.
Vaccine
. 2022 Dec;
41(2):290-293.
PMID: 36509640
We included 852 patients in a prospectively recruiting multicenter matched case-control study in Germany to assess vaccine effectiveness (VE) in preventing COVID-19-associated hospitalization during the Delta-variant dominance. The two-dose VE...
10.
Reichert F, Stier O, Hartmann A, Ruscher C, Brinkmann A, Grossegesse M, et al.
PLoS One
. 2022 Nov;
17(11):e0277699.
PMID: 36395156
Background: Superspreading events are important drivers of the SARS-CoV-2 pandemic and long-range (LR) transmission is believed to play a major role. We investigated two choir outbreaks with different attack rates...